Daratumumab is a medication used in this trial to treat primary plasma cell leukemia. It is a type of targeted therapy known as a monoclonal antibody. Daratumumab works by attaching to a specific protein on the surface of cancer cells, helping the immune system to identify and destroy these cells.

Chemotherapy is a treatment that uses powerful drugs to kill cancer cells or stop them from growing. In this trial, chemotherapy is combined with other treatments to enhance its effectiveness against primary plasma cell leukemia.

Stem Cell Transplantation is a procedure used to replace damaged or destroyed bone marrow with healthy stem cells. In this trial, it is used after chemotherapy to help restore the bone marrow’s ability to produce healthy blood cells.

Primary Plasma Cell Leukemia – This is a rare and aggressive form of leukemia characterized by the presence of a high number of plasma cells in the blood. It originates from the bone marrow, where plasma cells, a type of white blood cell, become cancerous and multiply uncontrollably. The disease progresses rapidly, often leading to symptoms such as fatigue, bone pain, and frequent infections due to the compromised immune system. As the abnormal plasma cells increase, they can cause damage to bones and impair kidney function. The condition is distinct from multiple myeloma, another plasma cell disorder, due to its more aggressive nature and the presence of plasma cells in the bloodstream. Early detection and intervention are crucial to managing the disease’s progression.